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CASE PRESENTATION
A 57-year-old man with end-stage renal disease secondary
to chronic interstitial nephritis was initiated on
hemodialysis in February 2006 for uremic symptoms. In
April 2006, his hemoglobin (Hgb) was 10.7 g/dl and
transferrin saturation was 12.7%. He was started on
subcutaneous follow-on epoetin-alfa, Wepox (Wockhardt
Limited India, Mumbai, India) and 10 weekly doses of
100 mg each of iron sucrose administered intravenously.
His Hgb increased to 12.3 g/dl within 2 months after the
initiation of epoetin. He then underwent coronary artery
bypass graft surgery for triple vessel coronary artery
disease. He received two units of packed cells during the
post-operative period because of a decrease in the Hgb
level to 8.2 g/dl. He was continued on epoetin at the same
dose. Three months later the Hgb level later was 6.6 g/dl
(Figure 1). Two units of red blood cell transfusion and
intravenous iron were administered, and Wepox was
continued. In December 2006, his Hgb decreased further
to 4.9 g/dl. Further work up of his anemia revealed that a
stool sample for occult blood was negative, an upper
gastrointestinal endoscopy showed an antral ulcer,
and gastric biopsy for Helicobacter pylori was positive.
He was treated with ampicillin, tinidazole, and omeprazole
for 10 days. A repeat endoscopy, 1 month later, revealed
a healed duodenal ulcer. A peripheral smear showed
reduced reticulocytes (0.8%) with normal platelet and
myelocyte series. His serum transferrin saturation was 97.8%.
lactate dehydrogenase was 385 U/l. Parvovirus B19 serology
was negative (IgM level was 9.3 U/ml (negative if less
than 17 U/ml)).
He received, on an average, 4 units of packed red cells
per month. A bone marrow trephine (Figure 2a) and
aspirate (Figure 2b) showed a selective depletion of
erythroblast precursors with normal granulopoiesis and
megakaryopoiesis suggestive of pure red cell aplasia
(PRCA). Wepox was withheld. His serum erythropoietin
level was 558 mU/ml (normal range 10–30 mU/ml). The
serum anti-erythropoietin antibody assay was positive
(0.9% c.p.m. at 1:100 dilution and 4.3% c.p.m. at 1:20
dilution by radioimmunoprecipitation assay (RIPA)).
CLINICAL DIAGNOSIS
Pure red cell aplasia due to Wepox.
CLINICAL FOLLOW-UP
After discontinuation of Wepox, he received 6 units of blood
transfusion and azathioprine at a dose of 300 mg per day,
after which his hemoglobin (Hgb) increased to 9.3 g/dl
within 2 weeks. He then underwent live unrelated renal
transplantation in January 2007, 2 weeks after stopping
Wepox. Since then, he has been managed on triple drug
immunosuppression comprising of tacrolimus, mycopheno-
late mofetil, and prednisolone. The post-transplant course
has been notable for two episodes of acute rejection, which
responded to methylprednisolone. After his kidney trans-
plant, he is not anemic. His Hgb and serum creatinine at
5 months post-transplant were 12.7 g/dl and 0.9 mg/dl,
respectively.
DISCUSSION
This presentation highlights the occurrence of PRCA with
follow-on epoetins (FOEs). In Europe, FOEs are also referred
to as biosimilar epoetins. In our patient, PRCA developed
because of neutralizing IgG antibodies to the protein
component of administered FOE, Wepox, that cross-reacted
with endogenous epoetin. The precise mechanism for PRCA in
patients treated with FOEs has not been elucidated. However,
because PRCA from innovator epoetin appears to have
resulted from problems in the manufacturing and storage of
epoetin that have since been addressed, it is likely that this
could also be the case with FOE, such as Wepox. Additionally,
because FOEs are largely marketed in emerging countries
where there is limited pharmacovigilance, surveillance for cases
of FOEs-induced PRCA takes on even greater significance.
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Figure 1 | Hgb level over time in the index case. Clinical course of the index patient with PRCA due to FOE showing schematic depiction
of Hgb levels during the pre-transplant and post-transplant period, and the dose and route of administration of follow-on epoetin.
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Figure 2 | A model for pathogenesis of PRCA due to innovator and follow-on epoetins with bone marrow findings of the index
patient. PRCA can develop due to innovator epoetin through two mechanisms. (1) Development of cross-reacting antibodies prevents both
endogenous epoetin and administered epoetin from binding to its receptor. (2) As yet, unknown factors suppressing erythroid precursors in
the bone marrow. The insets are the pictures of the index patient. The bone marrow specimen obtained by trephine biopsy (panel a
hematoxylin and eosin stain) is normocellular, with a marked erythroid hypoplasia, including the absence of early forms and contains
megakaryocytes and myeloid elements. The bone marrow aspirate showing the same findings (panel b Giemsa stain).
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PURE RED CELL APLASIA SECONDARY TO EPOETIN
Pure red cell aplasia (PRCA) is syndrome of marrow failure
characterized by the selective reduction or absence of
erythroid precursors. There is maturation arrest at the
basophilic pronormoblastic phase in the bone marrow that
is associated with reticulocytopenia and anemia. PRCA was
originally described by Kaznelson1 in 1922 as an entity
distinct from aplastic anemia. In the 1930s, Krantz et al.2,
characterized the immune mechanisms for the PRCA by
identifying anti-erythroid precursor cell antibodies and
T-cell-mediated inhibition of erythropoiesis. Two forms of
PRCA have been reported: acquired and congenital. The
congenital form of PRCA, also termed Diamond–Blackfan
anemia, is sporadic in onset and presents in childhood with
severe anemia. It is hypothesized that these patients have
poor differentiation of red cell precursors. More than 50% of
these patients demonstrate craniofacial, thumb, or neck
anomalies and genitourinary malformations.3 Many of these
patients respond to corticosteroids. The acquired form of
PRCA may result from various etiologies (Table 1). Although
most cases are considered idiopathic, in a series by Lacy
et al.4, T-cell large granular lymphocytic leukemia, thymoma,
chronic lymphocytic leukemia, and non-Hodgkin’s lympho-
ma were among the commonest causes in 47 adult patients
with acquired PRCA. The pathogenesis of PRCA in these
patients is not clear. Some of the suppressive effects on
erythroid progenitors in PRCA are mediated by IgG
autoantibodies or cytotoxic T lymphocytes.4 Among the
drug-related causes, PRCA is most frequently the result of an
idiosyncratic reaction with phenytoin.
Innovator epoetin (Epoetin-alfa; Epogen) was introduced
by Amgen (Amagen Inc., thousand oaks, CA, USA) in 1989
for the treatment of chronic kidney disease anemia. Initially,
cases of PRCA were anecdotally reported.5 Subsequently,
Casadevall et al.6, published the Food and Drug Administra-
tion (FDA) Med Watch data on a series of patients with
epoetin-related PRCA. Most cases of PRCA have been
reported from outside the United States with epoetin-alfa
and have been attributed to the substitution of Tween in
place of human serum albumin as a stabilizer for epoetin (of
note, Tween 80 is still used as a stabilizer for non-US epoetin-
alfa and Tween-20 for epoetin-beta). Although epoetin-
related PRCA has been reported in patients treated with other
innovator epoetin molecules, including darbepoetin alfa and
epoetin-beta, the frequency was much lower than epoetin-
alfa, and remained constant through the years. The inter-
action of Tween and the uncoated rubber in pre-filled
syringes appears to cause leachates. These leachates have been
implicated in causing aggregation of epoetin molecules that
then enhance their antigencity.7,8 Although these patients
develop antibodies to the exogenously administered epoetin
that cross-react with the endogenous epoetin, they also have
factors that inhibit erythroid precursors.6 It is hypothesized
that neutralizing anti-erythropoietin antibodies block the
interaction between erythropoietin and its receptor, leading to
ineffectiveness of the circulating erythropoietin. Furthermore,
it is postulated that the production of anti-erythropoietin
antibodies against endogenous epoetin occurs more fre-
quently in patients administered exogenous epoetin. It is
postulated that anti-erythropoietin antibodies cross-react
against the protein component of the exogenous recombinant
epoetin. Other possible mechanisms that have been raised
include interruption of the cold chain, presumably resulting
in modification in the folding of the epoetin molecule, and
the use of the subcutaneous route of administration.
Subcutaneous administration of epoetin also appears to
contribute to the development of PRCA.6 Nevertheless,
following modifications in the manufacturing process,
reinforcement of cold chain, and decrease in the subcutaneous
administration, there has been a dramatic reduction (480%)
in PRCA.9 It is intriguing that most epoetin-associated PRCA
cases are reported in patients with chronic kidney disease and
not those treated for anemia of chronic disease of other
etiologies. In addition, not all patients with chronic kidney
disease develop PRCA, suggesting that there may be some
genetic predisposition to the susceptibility to PRCA. Alter-
natively, epoetin aggregation from leachates may not represent
the complete explanation for the mechanism of PRCA and
additional pathways for PRCA will need to be sought out.
DIAGNOSIS OF EPOETIN-RELATED PRCA
The 2006 Kidney/Dialysis Outcome Quality Initiative
(K/DOQI) guidelines, which are similar to the European
Best Practice Guidelines published in 2004, suggest that
PRCA should be suspected in patients receiving erythro-
poiesis stimulating agents therapy for more than 4 weeks
who develop a sudden rapid decline in Hgb level (at the rate
of 0.5–1.0 g per 100 ml per week), or require red blood cell
transfusions at a rate of approximately 1–2 per week in the
Table 1 | Causes of PRCA in adults24
Drugs
Hematological conditions/
malignancy
Phenytoin/valproic acid Large granular lymphocyte leukemiaa
Trimethoprim-sulfomethoxazole Lymphoreticular malignancy
Chloramphenicol Myelodysplastic syndromea
Isoniazid Metastatic carcinoma
Ziduvudine Thymomaa
Chlorpropamide Systemic lupus erythematosusa,b
Azathioprine Rheumatoid arthritisa,b
Procainamide Juvenile rheumatoid arthritisa,b
Recombinant human
erythropoietin
Multiple endocrine insufficiency
syndromesa,b
Infections
Parvovirus B19 infection
Hepatitis (pregnancy)
Adult T-cell leukemia virus
(idiopathica)
Epstein–Barr virus
(idiopathica)
PRCA, pure red cell aplasia.
aImportant causes of PRCA.
bAutoimmune diseases.
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context of normal platelet and white blood cell counts and an
absolute reticulocyte count less than 10,000/ml.10,11
The diagnosis of PRCA is usually made from the
examination of the peripheral smear and the bone marrow
aspirate. The peripheral smear shows normocytic anemia and
the absence of polychromasia with a reticulocyte count of
o3% or 10,000/ml. Monitoring of serial reticulocyte counts
in patients suspected of PRCA is helpful in early diagnosis of
PRCA. The bone marrow aspirate demonstrates the presence
of maturation arrest of the erythroid series at the level of
basophilic pronormoblast phase with preserved myelopoiesis
and megakaryopoiesis. Bone marrow trephine has a higher
yield than the bone marrow aspirate, and is also helpful in
diagnosing secondary causes of PRCA, such as Parvovirus
B19 infection (giant pronormoblast), lymphomas and
metastatic carcinomas, and myelodysplastic syndromes. As
there is inadequate utilization of iron, serum ferritin and
transferrin saturation are frequently very high and are
characteristic of this condition.
In patients on epoetin, the presence of anti-erythropoietin
antibodies coupled with the presence of typical bone marrow
findings is usually sufficient to make the diagnosis of epoetin-
related PRCA. The assays used for the detection of anti-
erythropoietin antibodies can be broadly divided into in vitro
assays, such as antibody detection and functional assays, and
in vivo assays. The following three assays: RIPA, the enzyme-
linked immunosorbent assays, and the biosensor immuno-
assay are the most commonly used in vitro-neutralizing
antibody detection assays. RIPA is considered the most
specific and sensitive, and most commonly recommended
test for detection of anti-erythropoietin antibodies. RIPA is
based on competitive inhibition. The results for this assay are
given for three individual determinations of anti-EPO
antibody levels. A positive antibody is X0.9% c.p.m. bound
in the above assay. A negative antibody is p0.6% c.p.m.
bound in the above assay. Results that are between positive
and negative are considered borderline. This test is not only
specific but also very sensitive, as it can detect the presence
of high-affinity anti-EPO IgG at a concentration as low as
10 ng/ml. Enzyme-linked immunosorbant assays is a quanti-
tative method with easy implementation due to the simplicity
of the procedure. However, high interassay variability and
dependence on the laboratory conditions make it less
sensitive than RIPA. The introduction of the ‘bridging ELISA’
has only modestly increased the specificity of the test. A
biosensor immunoassay has recently been used for the
detection of EPO antibodies. It is useful for characterization
of the antibodies such as affinity and isotype. The major
disadvantages are that it is expensive and its specificity (may
detect non-pathogenic antibodies). The neutralizing capacity
of anti-erythropoietin antibodies is best assessed by the cell
proliferation assays.
FOLLOW-ON BIOLOGICS
In the developing world and more recently in Europe, follow-
on biologics are available for the treatment of anemia of
kidney disease. These follow-on biologics are proteins that
are similar but not identical to an already licensed or
approved innovator biologic (the innovator biologic) with
respect to bioequivalence and/or therapeutic equivalence.
Innovator biologics are developed through biotechnology
practices, including recombinant human technology, gene
technology, or antibody methods. Each area of the manu-
facturing process of a biopharmaceutical, such as choice of
the expression vector, cell fermentation, host cell line, protein
purification protocols, sterile filling, and drug product
formulation, is a determining factor.12 Subtle variations in
temperature, cell culture conditions, or even transport or
storage conditions may result in significant changes in the
clinical efficacy, biological activity, or immunogenicity of the
product in some cases.13–15 Thus, follow-on biologics, such as
FOEs, originating from different manufacturers may be
associated with subtle differences in their biochemical
composition, which could translate into therapeutic differ-
ences.16,17 In addition, the differences in conformation of the
biologic could potentially impact on their immunogenicity.
FOLLOW-ON EPOETINS
FOEs are targeted to mimic the action of the original
innovator epoetins. FOEs are frequently produced by local
biotechnology companies and licensed by the local country’s
FDA or equivalent drug regulatory agency. In developing
countries, FOEs are an inexpensive substitute for innovator
epoetins. Indeed, the price may be discounted as much as
60% over the cost of the innovator epoetin. On the other
hand, in Europe, FOEs are likely to be priced more closely to
the innovator epoetin. Hitherto, prior to the patient
described here, PRCA had not been reported with FOEs.
However, FOEs may differ from the innovator biologic with
respect to tertiary or quaternary folding, the cell lines used to
express the protein, glycosylation content, and the degree of
aggregation and isomer content. Others have also documen-
ted variable physical characteristics, such as pH, osmolality,
and isoelectric charge, with FOE18,19. These subtle differences
could provide plausible explanations for potential immuno-
genicity for FOEs. Indeed, it is most likely that the same
mechanisms that accounted for the immunogenicity of
innovator epoetin could also explain the immunogenicity
of FOEs.
Each manufacturer of a FOE develops their own
manufacturing processes and has their own quality surveil-
lance protocols; this has the potential to generate subtle
differences that could impact on the content and activity of
the biologic. With the inability to reproduce identical
molecule, efficacy measures and standardized analytical and
pre-clinical tests for FOEs have been insufficient to
demonstrate the comparability of two biological pro-
ducts.19,20 In a study that we have conducted, FOE samples
procured from pharmacies in Korea, Thailand, Vietnam,
India, Philippines, Indonesia, Iran, Yemen, Jordan, Lebanon,
and Columbia revealed variable physical characteristics with
respect to pH, osmolality, and isoelectric charge. Some of
1620 Kidney International (2008) 74, 1617–1622
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these FOEs revealed varying potencies, higher endotoxins,
and aggregates compared with epoetin-alfa.18 Since the
European Union (EU) has developed more stringent
standards for the monitoring of quality, it is unlikely that
this variability in quality and problems with endotoxin
contamination will be observed with FOEs that are marketed
in Europe, although pharmacovigilance is still warranted. An
inherent risk involved in the use of any biologic is its
immunogenic potential. Immunogenicity can be due to many
factors, such as altered chemical structure of the molecule,
physical degradation, and chemical decomposition, apart
from an effect of protein purification and product formula-
tion.21 The role of epoetin aggregates, leachates from rubber
lined pre-filled syringes, and the subcutaneous route of
administration have all been implicated in the etiology of
PRCA secondary to innovator epoetins. Although FOEs are
often used by practitioners for economic reasons, the varying
potency observed in tested lots of the FOE raises questions
about whether there is sufficient scrutiny of FOEs that are
currently being marketed, especially in developing nations.
TREATMENT OF EPOETIN-RELATED PRCA
There is no consensus on optimal therapy for PRCA. As in
our patient, withdrawal of all kinds of erythropoiesis-
stimulating agents was the critical step because prior
observations demonstrate that the cross-reacting antibodies
bind the diverse range of epoetin molecules, including
darbepoetin alfa.22 Despite reports of allergic reactions after
re-introduction of erythropoietin, studies suggested success
with reintroduction of epoetin after complete disappearance
of anti-erythropoietin antibodies.23 The ESRD patient in
whom kidney transplantation is not feasible is especially
challenging from a management standpoint. Although spon-
taneous remissions are rare, immunosuppressive treatment
accelerates recovery from erythropoietin-induced PRCA.23,24
In these patients, there is an agreement that long-term
treatment with steroids and cyclophosphamide is warranted.
Other treatment modalities include plasmapheresis, cyclo-
sporine, intravenous gamma globulins, and rituximab.
Hematide is a pegylated synthetic peptide, which has been
developed as an erythropoiesis-stimulating agent. No reports
of PRCA have appeared in the literature, perhaps because
hematide has novel amino acid sequences that are not related
to endogenous erythropoietin. Although preliminary studies
in rat models with hematide were promising with the
correction of antibody-induced anemia (rat PRCA model),
studies with long-term follow-up, especially in patients with
chronic kidney disease, are not available.25,26 An algorithm
based on the recommendation of the 2004 Revised European
Best Practice Guidelines for the Management of Anaemia in
Patients with Chronic Renal Failure is described in Table 2
(specific hematologic and/or bone marrow criteria are
detailed in the original guideline document).10,11
In summary, with the patent expiry of innovator epoetins,
FOEs will be an important option for the treatment of
chronic kidney disease anemia. Physicians must be vigilant
because FOEs may result in PRCA. Furthermore, although
pharmacovigilance is a daunting and potentially expensive
task for drug regulatory authorities, especially for countries
in the developing world, scrutiny of the manufacturing and
storage processes for epoetin is essential. Perhaps even more
important in ensuring the long-term safety of biologic
products, especially FOEs, is the development of a post-
marketing surveillance infrastructure that allows for pharma-
covigilance. It seems a price worth paying.
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